The tip of the iceberg: predicting PARP inhibitor efficacy in prostate cancer
Affiliation
Oncology Institute of Southern Switzerland, Bellinzona, SwitzerlandIssue Date
2019
Metadata
Show full item recordCitation
Gillessen S, Bristow RG. The tip of the iceberg: predicting PARP inhibitor efficacy in prostate cancer. Lancet Oncol. 2020;21(1):17-9.Journal
Lancet OncologyDOI
10.1016/S1470-2045(19)30780-6PubMed ID
31806542Additional Links
https://dx.doi.org/10.1016/S1470-2045(19)30780-6Type
OtherLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/S1470-2045(19)30780-6
Scopus Count
Collections
Related articles
- Acute Myeloid Leukemia After Olaparib Treatment in Metastatic Castration-Resistant Prostate Cancer.
- Authors: Zhu J, Tucker M, Wang E, Grossman JS, Armstrong AJ, George DJ, Zhang T
- Issue date: 2017 Dec
- Stratifying prostate patients for olaparib.
- Issue date: 2015 Jun
- PARP Inhibitors for Advanced Prostate Cancer: Validating Predictive Biomarkers.
- Authors: Mateo J, Carreira S, de Bono JS
- Issue date: 2019 Oct
- Olaparib Targets Some Advanced Prostate Cancers.
- Issue date: 2016 Jan
- Re: Konrad H. Stopsack. Efficacy of PARP Inhibition in Metastatic Castration-resistant Prostate Cancer is Very Different with Non-BRCA DNA Repair Alterations: Reconstructing Prespecified Endpoints for Cohort B from the Phase 3 PROfound Trial of Olaparib. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.09.024.
- Authors: de Bono J, Hussain M, Kang J
- Issue date: 2021 Mar